Leading the way to
eliminate herpes.

Prior to founding Rational Vaccines, Mr. Fernandez served as the managing director of Mega films, the production arm of Spanish Broadcasting System (SBSA), and CEO of Duende Media, Inc. where he structured over US $100M of film and television financing. Mr. Fernandez is a 9-time EMMY award winning writer/director/producer and the executive producer of the 2014 academy award winning documentary “The Lady In Number Six”.

Mr. Jarry combines a business background (12 years with Accenture) with 25 years of life sciences experience including Novartis, Bayer, Bristol-Myers Squibb and midsize biopharma. His responsibilities covered Strategy, M&A, regional leadership and finance-associated roles. He has had financial responsibility for sales in excess of $1.4 billion and M&A in excess of $1.1 billion. He has negotiated and managed agreements with nine-digit annual value in North and Latin America, Western and Eastern Europe, China and Japan. Mr. Jarry’s experience in vaccines includes addressing the H1N1 pandemic flu of 2009 with authorities in Europe and ex USSR.

Kerstin Westritschnig, MD is specialized in clinical immunology and has 20 years of working experience in R&D, thereof 15 years in vaccine development. Her areas of expertise are vaccines, infectious disease, immuno-oncology and biologics. She has served as the medical lead for design and conduct of approximately 20 clinical vaccine studies from Phase I to Phase IV in more than 7 infectious disease indications. She was involved in two successful marketing/new drug applications at FDA and/or EMA (Japanese encephalitis vaccine, IXIARO ®; GD2-antibody for the treatment of neuroblastoma, Qarziba ®). She previously served as Senior Vice President and member of the Executive Committee of Intercell AG, Valneva SE and as Chief Medical Officer of Apeiron Biologics AG.

DPhil MEng PG Cert (IP) RAC (US) FRSA FRSB

Dr. David Brindley is an experienced life science C-level executive and Board Member, specializing in cell/gene/viral therapies and digital health. Under Dr. Brindley’s leadership, multiple therapeutics and medical devices have achieved market approvals in the US, EMEA and ASEAN supporting transactions, including IPOs, trade sales and joint ventures. Dr. Brindley has published more than 100 peer reviewed publications in high impact journals, including Nature, Nature Biotechnology and Cell Stem Cell.

Prior to joining Rational Vaccines, Dr. Gershburg was an Associate Professor (with tenure) at Southern Illinois University School of Medicine from 2007 to 2017. Dr. Gershburg’s area of expertise is Virology (with focus on DNA viruses) and Antivirals. His research was supported by National Institutes of Health and American Cancer Society. Dr. Gershburg authored over 20 peer-reviewed publications and was a co-author on all the key publications associated with the company’s lead product (RVx-201). Dr. Gershburg continues his professional public service on editorial boards of Antiviral Research and PLoS ONE, as well as an Ad Hoc Reviewer for the Italian Ministry of Health.

Rodolfo Dominguez is an accomplished executive leader with over 25 years of experience building and transforming global organizations to innovate and grow.

The depth of his experience leading successful operations across the Americas Region, Asia Pacific, China, and Europe, allows him to understand and harness the unique drivers for success in a wide variety of markets and cultures.

In his most recent position as Global Head of Digital Solution Centers and Chief Digital Officer (CDO) for Daimler Mobility AG, Rodolfo was responsible for providing enterprise-wide leadership for the design, development, and delivery of digital client-facing capabilities across the company’s €150.6 billion global business.

Rodolfo built his expertise in finance, operations, business development, general management, and business transformation through multiple executive roles with Daimler / Mercedes-Benz Financial Services in the USA, Canada, and Mexico where he managed large, multi-disciplinary expert teams. His leadership and successful launch of some of the largest, most complex digital transformation programs ever undertaken by the company led to his appointment as Global CDO, based in Stuttgart, Germany.

Rodolfo believes that business is built on clear strategy and strong, trust-based relationships. He excels at building and maintaining personal connections at all levels and empowers, mentors and advocates for his team thus creating a culture that thrives on diversity and inclusion.

Dr. Konstantin “Gus” Kousoulas received his BS in Physics from Fairleigh Dickinson University in Teaneck, NJ, and his MS and PhD degrees from Pennsylvania State University in Biophysics and Molecular Cell Biology, respectively. He received postdoctoral training at the University of Chicago working in Dr. Bernard Roizman’s laboratory and at the University of California at San Francisco with Dr. Lenore Pereira, where later he was promoted to Research Assistant Professor. He joined Louisiana State University in Baton Rouge and became full professor in 1994. He is currently Professor of Virology and Biotechnology at the LSU School of Veterinary Medicine and Director of the Division of Biotechnology & Molecular Medicine with adjunct appointments at the Department of Biological Sciences, College of Basic Sciences at LSU Baton Rouge, the Department of Microbiology and Immunology at the LSU Health Sciences Center in New Orleans, and the LSU Health Sciences Center’s Stanley S. Scott Cancer Center in New Orleans. Dr. Kousoulas has substantial expertise in animal models of viral and bacterial infections including non-human primates. Currently, he serves as the NIH National Scientific Advisory Board (NSAB) of the Southwest National Primate Research Center and has previously served as Chair of the NSAB of the Tulane National Primate Research Center. His primary research interests are focused on the molecular biology and immunopathogenesis of human herpes viruses. He has extensively utilized herpes simplex viral vectors for vaccine development and cancer treatment. He has constructed and patented herpes simplex viruses that have been shown to be highly efficacious as preventative and therapeutic vaccines for herpes genital and ocular infections and as potent adjuvants for cancer immunotherapy approaches in animal models. Other research interests include computational approaches to protein structure and function, the use of virus-like particles for drug delivery, and the utilization and development of bioinformatics and advanced diagnostic solutions for infectious diseases and cancer.

Dr. Gerhard Hager is a serial entrepreneur and an expert in non-clinical research and development with a vast experience in the performance of preclinical programs for a wide range of drug candidate classes and therapeutic strategies. He is CEO of The NCD Company. He was Head of Toxicology at Baxter, Baxalta and Shire and has successfully overseen the development of a variety of products in different development stages, from drug discovery right to market approval at EMA, FDA and PMDA. Before that he was founder, scientific director and CEO of Aurigon and the Aurigon Group, an international non-clinical full-service research institute (CRO). He holds a PhD in Zoology from the LMU Munich and the Max-Planck-Institute of Psychiatry.

Dr. Hager supports Rationale Vaccines in the non-clinical development of his promising therapeutic HSV-2 vaccine candidate RVx201.

Christy Mazzarisi currently is the Vice President, Corporate Quality managing the Quality Unit at Rational Vaccines. She is an innovative and accomplished Quality Systems Professional with a broad background in Pharmaceutical and Laboratory sciences (specializing in business development) with R&D and commercial manufacturing (sterile and non-sterile) experience with over 15 years industry practice and 8 years consulting for top tier pharmaceutical companies. Overall background and specialties include GMP & GLP, which has led to strategic management of major programs such as gap analysis and transformation of Annual Product Review systems, SOP transformation and optimization, QMS frameworks, and operational systems audits. She is passionate about continuous improvement activities and consistently building quality into each area of the life sciences. She is also a major advocate and volunteer and committee member for a few non-profit organizations to support education and awareness of neurological disorders and critical illnesses in children. Mrs. Mazzarisi is also the Chair of ASQ’s Women in Quality forum; which caters to building leadership skills in the quality profession across the sciences.

Brandie currently works as a Lab Manager at Rational Vaccines. Her role involves overseeing laboratory functions, serving as a Biosafety Officer, and developing and executing experiments aligned with research goals. She has a background in Biological Sciences and currently holds a B.S in Biology from the University of Illinois at Springfield. Prior to joining Rational Vaccines, Brandie spent 5 years working in healthcare where she functioned as a Medical Scribe and Certified Emergency Medical Technician (EMT) in the Emergency Department. Brandie has had a longstanding interest in healthcare and has devoted her post-baccalaureate career to the field. She is passionate about health and wellness, disease prevention and the overall improvement of health care systems, particularly in underserved communities.

Quinn began her career in the Life Sciences industry in 2002 in an administrative role in Clinical Operations with a global Clinical Research Organization. In 2004, after having gained experience in the end to end clinical trial process, she moved into a system-focused role as a Global Trainer for the implementation of the Clinical Trial Management System. In 2012, Quinn obtained her Certified Business Analysis Professional (CBAP) certification, and her BSA in Information Systems in 2014 from Kaplan University. Over the course of her 18-year career in a regulated environment, she has led projects ranging from custom system development, data integration, mobile application development, data migration, off-the-shelf implementation, dashboard development and predictive analytics. Quinn’s expertise lies where people, process and technology come together in new and innovative ways.

Diane Abbitt has expertise in the areas of strategic planning, administrative law, government and public sector law, real estate law, and business law. Abbitt has assisted such companies as Mobil Exxon, Fujisawa Pharmaceuticals, USA, Lynch/Frost Productions, Inc. and the Bio Tech Trade Union Association through the maze of governmental regulation and the legislative process. Other corporate clients have included Porton Medical Laboratories, ICN Pharmaceuticals, and Paragon Group. Over the last almost forty years, Ms. Abbitt has been a community activist serving on the boards of the National Organization for Women, Co-chairing MECLA, the first Political Action Committee in the country dedicated to achieving equality and secure legal protections for LGBT people and was the founding Co-President of AIDS Project Los Angeles.

Co-founder & Chief Technology Officer of Iridia Inc. Dr. Predki is a seasoned biotech executive and entrepreneur with 25 years of technology and product development experience, and a co-founder of 3 successful start-ups.

Dr. Singhvi is an Operating Partner at Flagship Pioneering, a unique Boston-based life sciences innovation firm. At Flagship Pioneering, Dr. Singhvi is responsible for operating young start-up companies launched from Flagship’s innovation foundry, Flagship Labs.

Prior to Flagship, Dr. Singhvi was the Chief Operating Officer of Takeda’s Vaccine Business Unit where he was responsible for global vaccine operations at the Takeda Pharmaceutical Company. During his 6-year tenure at Takeda, the vaccine business grew to over 500 employees and created an impressive late-stage pipeline of vaccine candidates against dengue, norovirus and Zika. Before joining Takeda, Dr. Singhvi was President and CEO of Novavax, Inc. a clinical stage vaccine company listed on the Nasdaq (NVAX). Under his leadership, Novavax transformed from a failed specialty pharmaceutical business to a vaccine development company with vaccine candidates against influenza (funded by BARDA) and respiratory syncytial virus (RSV). Dr. Singhvi’s professional career began at Merck & Co in 1994, where he held several positions in R&D and manufacturing.

Dr. Singhvi serves on the Executive Advisory Board of the Leonard Davis Institute (LDI) of Health Economics at the University of Pennsylvania and as an advisor to the Office of Technology Transfer at the University of Maryland, Baltimore. He is a mentor instructor in the Undergraduate Projects Opportunity Program (UPOP) at MIT. He serves as a visiting lecturer at the University College London (UCL) and is also on the faculty of the University of Sienna’s Master’s course on Vaccinology.

Dr. Singhvi graduated as the top-ranked chemical engineer from IIT, Kanpur, India and obtained both his MS and ScD chemical engineering degrees from MIT. He received an MBA from the Wharton School of the University of Pennsylvania, where he graduated as a Palmer Scholar.

Professor Lionel Raj is a Regional Medical Director of Dr. Agarwal’s Eye Hospital, Tirunelveli, India. He is one of the leading corneal transplantation surgeons in the world. He served as the Chief of Department of Cornea and Ocular Surface Diseases from 2006 to 2010 at Aravind Eye Care System, Tirunelveli. He has completed over a 100,000 surgeries in his career and has won 12 international and several national awards in the field of ophthalmological research.

Georg Holländer trained in both Pediatrics and Experimental Immunology in Switzerland and the U.S. He held academic positions at Harvard Medical School, Boston, U.S. and the University of Basel, Switzerland before he joined the University of Oxford, UK in 2010. Since 2019, he is also the Director of the Botnar Research Centre for Child Health. His research is focused on the development and function of the immune system, with a particular interest in how our immune system can effectively distinguish between the body’s own cells and potentially harmful antigens of other origins.

Mahira Hamdy El Sayed is a Professor of Dermatology at Ain Shams University , and a board member of the International Psoriasis Council .She is also the Head of the Egyptian fellowship program.

She was the head of the department from 2017 for one year,and she also served as the head of the Egyptian society of Dermatology and Venereology for 2 years. She runs a weekly psoriasis clinic which serves as a referral center registering the patients and overseeing their follow up and management .She is also a member of GRAPPA, and is on the editorial board of the International Journal of Dermatology . She is also the representative of the Middle East in the Global Psoriasis Atlas , a project directed by Professor Christopher Griffiths Manchester England .

She has several national and international publications and has presented several papers in both national and international conferences She is very committed to improving the outcomes for patients with psoriasis in Egypt and has on numerous occasions lobbied the government to improve access to healthcare and medicine.

Todd Margolis MD, PhD is the Albert and Edith Wolff Distinguished Professor and Chair of the John F. Hardesty MD Department of Ophthalmology and Visual Sciences at Washington University in St. Louis.

Dr. Margolis has a long-standing interest in regulation of infection with HSV. Prompted by his neuroscience background, his lab research has focused on how HSV and sensory neurons interact to regulate productive and latent viral infection.

In his clinical practice, Dr. Margolis cares for patients with complicated infectious and inflammatory eye disease. He is particularly well known for his clinical expertise in the areas of HSV and VZV eye disease. He is currently working as the protocol chair for an AIDS Malignancy Collaborative study (AMC -104), a feasibility study of OSSN surgical excision in HIV infected patients in 4 countries in west Africa.

During his career, Dr. Margolis has supervised 17 pre-doctoral students and 16 postdoctoral fellows in his lab, as well as over 100 clinical fellows (including 31 international fellows), many of whom conducted clinical research. Four of his fellowship trainees are currently chairs of departments of ophthalmology. He has over 160 peer reviewed publications in the scientific literature (H factor=46) and has received a number of awards, including the Jules Stein Vision Research Award, RPB Career Development Award, RPB Lew Wasserman Merit Award, RPB Senior Scientific Investigator Award, Faculty AOA Award and 2012 Heed Award. He has served on a number of NIH study sections, NEI council, as an executive editor of the American Journal of Ophthalmology, and as president of ARVO.

James Robinson has 35 years of experience in biological manufacturing, late-stage development and quality. He has held executive level positions with Sanofi Pasteur, Merck and Novavax. His most recent role was Vice President of Technical and Product Operations for Merck Vaccines, Biologics, and Sterile Manufacturing network from 2010–2015. Collectively, Jim has managed the production of nearly 2 billion doses of nearly every vaccine, including influenza, tetanus, meningitis, chicken pox and shingles, rotavirus, MMR, human papilloma virus, hepatitis A and B, and developmental recombinant protein vaccines, spending much of that time “industrializing” vaccine and therapeutic protein manufacturing technologies, expanding capacity, improving reliability and reducing costs. In December 2012, he was featured in Life Science Leader Magazine for transforming Merck’s approach to vaccine manufacture. Jim has a BS and MS in Chemical Engineering from Lehigh University and is a licensed Professional Engineer.

Dr. Bernstein attended medical school at the State University of Buffalo and then did a pediatric residency at the University Southern California in Los Angeles and the New England Medical Center in Boston. During his infectious diseases fellowship at UCLA he became interested in vaccines and antivirals. He moved to Cincinnati in 1983 and began his work studying rotavirus infections and vaccines as well as herpes virus infections. During this time, teaming with Dr. Richard Ward, he developed a rotavirus vaccine that eventually became Rotarix, a vaccine used around the world. Dr. Bernstein has been the principal investigator for the NIH contract to study vaccines and antivirals for the treatment of herpes virus infections in animal models since 1990. During this time, he refined the guinea pig model of genital HSV. Uniquely, he has also been the principal investigator for the NIH funded contract to evaluate vaccines and treatments (VTEU) in clinical trials. As a clinical investigator he has performed several trials of both prophylactic and therapeutic HSV vaccines. Dr. Bernstein ascended the ranks and became a Professor and the Director of the Division of Infectious Diseases at Cincinnati Children’s Hospital Medical Center (CCHMC). He has published over 300 manuscripts and numerous chapters focused on vaccines and antivirals.

Dr. Stanley A. Plotkin is an Emeritus Professor of the University of Pennsylvania. Until 1991, he was Professor of Pediatrics and Microbiology at the University of Pennsylvania, Professor of Virology at the Wistar Institute and at the same time, Director of Infectious Diseases and Senior Physician at the Children’s Hospital of Philadelphia. For seven years, he was Medical and Scientific Director of Sanofi Pasteur based at Marnes-la-Coquette, outside Paris. He is now a consultant to vaccine manufacturers and non-profit research organizations.

He is a member of the Institute of Medicine of the National Academy of Sciences and the French Academy of Medicine. His bibliography includes over 800 articles, and he has edited several books including a textbook on vaccines. He developed the rubella vaccine now in standard use throughout the world, is codeveloper of the pentavalent rotavirus vaccine, and has worked extensively on the development and application of other vaccines including anthrax, oral polio, rabies, varicella, and cytomegalovirus.

Alan has extensive experience from a 32-year drug development career in both small biotech companies and large pharmaceutical organizations. He is a veteran in the development and execution of development programs for vaccines and rare disease therapeutics. Alan had a prominent role in the development of Prevnar® at Wyeth Vaccines and Bexsero® at Novartis Vaccines, and Elaprase® for the treatment of Hunter syndrome at Transkaryotic Therapies (now Shire/Takeda). He is currently Senior Vice President and Therapeutic Area Head for Rare Diseases at CureVac. Prior to CureVac, Alan served as Chief Medical Officer at Enzyvant and SutroVax (now Vaxcyte), and Vice President, Clinical Development at Translate Bio. Alan has held senior clinical development, research, and medical affairs roles at Shire, Novartis Vaccines, Altus Pharmaceuticals, Transkaryotic Therapies, BioChem Pharma, SmithKline Beecham Biologicals, and Wyeth Vaccines. He has authored more than 30 publications and book chapters on vaccines and rare diseases. Alan received his M.D. from the University of Miami School of Medicine; an M.A. and Ph.D. from the University of California at Davis; and a B.A. from the University of California at Berkeley. He also conducted postdoctoral research in microbial pathogenesis at the University of Texas Health Science Center at Dallas (now UT Southwestern Medical Center).

Dr. Luis Rios-Nogales Garces currently is the Chief Medical Officer managing Non-Clinical and Clinical Development, Regulatory Affairs, R&D Quality Assurance, Vaccine Safety, and Corporate Procurement. Prior to joining Rational Vaccines, Dr. Rios-Nogales served as Head of Global Development Operations at Takeda Vaccines. He has over 30 years of experience, with increasing senior roles in Clinical, Medical Affairs, Global Marketing, Regional Medical Office, Commercial and General Management at Sanofi, GSK and Astra Zeneca. Dr. Rios-Nogales was also Senior Vice President of Med Surg at Boston Scientific Corporation between 2006–2009. He has made a significant impact on the prevention and treatment of stroke, hypertension, Afib, CHF and VTD, through his active participation in large scale clinical projects. Notably, he was the Global Project Lead for the landmark Heart Outcomes Prevention Evaluation (HOPE) study, under the leadership of Professor Salim Yusuf of McMaster University.

Raj Patel trained in Sheffield and London in HIV Medicine and Sexual Health. He took up his current post of Consultant in Sexual Health & HIV Medicine (Solent Sexual Health) and Senior Lecturer in Sexual Health & HIV Medicine (University of Southampton) in 1993. His major clinical and research interests are Genital Ulceration syndromes, Genital Herpes Infections, Molecular Diagnostics, Limiting and managing transmission risks of STIs, Evaluation of novel pathways for managing patients. He is Immediate Past Chair of the Clinical Standards Unit of BASHH, Senior Counsellor (Past President) IUSTI World, Specialty Advisor to the Royal College of Physicians London, and serves on the editorial committees of a number of specialist journals and the European STI Standards and Guidelines Group. He has been the chair of the Herpes Interest Group of the British Association (BASHH) for over 20 years.
As chair of the Clinical Standards Unit for BASHH he has overseen the production and updating of all the organisation’s standards in the last 3 years. These standards form the basis of service commissioning arrangements nationally. He has redesigned and restructured postgraduate Sexual Health Training in the UK and has developed 2 internationally acknowledged assessments for postgraduate STI specialisation (Dip GUM and Dip HIV). He has developed a clinical centre of excellence that has completed ground-breaking research into herpes genital infections and the control of viral STI. He is the author of 5 major guidelines and a college monograph on preventing neonatal complications of herpes. He serves on the advisory committee to the European CDC advising on multinational control programmes for STI. He manages a substantial portfolio of Undergraduate and Postgraduate education.

John Boslego, MD has worked for more than 40 years in vaccine clinical research and development. Dr. Boslego was most recently Senior Vice President and Head of Development for Takeda’s Global Vaccine Business Unit. Prior to Takeda, he was Director of the Vaccine Development Global Program at PATH, where he built a vaccine development organization and advanced the development of vaccines against pneumococcus, rotavirus, ETEC, shigella, meningococcus, influenza, respiratory syncytial virus, polio and Japanese encephalitis. Prior to this, he served as executive director of Biologics, Clinical Research at Merck & Co., Inc., where he directed a global team that was responsible for the successful development and licensure of a portfolio that included a Haemophilus influenzae type b conjugate vaccine, various pediatric combination vaccines, a rotavirus vaccine, and the first HPV vaccine, among others. Dr. Boslego began his career at the Walter Reed Army Medical Center and Walter Reed Army Institute of Research. He served as the Director of the Armed Forces Research Institute of Medical Sciences (AFRIMS) in Bangkok, Thailand where he led research and development programs for treatments and vaccines against hepatitis A, malaria, dengue, rickettsial diseases, bacterial diarrheas, and HIV. Dr. Boslego’s final assignment in the US Army was as Deputy Director of the Walter Reed Army Institute of Research (WRAIR), where he directed research and vaccine development against a broad array of viral, bacterial and parasitic pathogens. Dr. Boslego received his medical degree from the George Washington University School of Medicine in Washington, DC and completed specialty training in Internal Medicine and Infectious Diseases.